Mitchell Capital Management Co. Acquires New Shares in Icon Plc $ICLR

Mitchell Capital Management Co. bought a new stake in Icon Plc (NASDAQ:ICLR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 9,297 shares of the medical research company’s stock, valued at approximately $1,627,000.

Other institutional investors also recently modified their holdings of the company. Artisan Partners Limited Partnership raised its position in shares of Icon by 67.4% in the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock valued at $1,045,039,000 after acquiring an additional 2,893,946 shares during the period. Principal Financial Group Inc. grew its holdings in Icon by 739.2% during the third quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock valued at $573,526,000 after purchasing an additional 2,886,755 shares during the period. Harris Associates L P bought a new stake in Icon in the second quarter valued at approximately $238,256,000. Norges Bank acquired a new stake in Icon in the second quarter worth $158,639,000. Finally, 1832 Asset Management L.P. boosted its position in shares of Icon by 587.9% during the second quarter. 1832 Asset Management L.P. now owns 1,151,328 shares of the medical research company’s stock worth $167,461,000 after purchasing an additional 983,950 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ICLR. Robert W. Baird set a $217.00 price objective on shares of Icon in a research report on Friday, January 9th. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. Truist Financial restated a “hold” rating and issued a $222.00 price target (down from $231.00) on shares of Icon in a report on Thursday, January 8th. TD Cowen lifted their price objective on Icon from $172.00 to $183.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Finally, UBS Group set a $220.00 target price on Icon in a research note on Friday, October 24th. Six research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat, Icon has an average rating of “Hold” and a consensus target price of $200.60.

Icon Price Performance

NASDAQ:ICLR opened at $133.14 on Thursday. The stock has a market capitalization of $10.75 billion, a PE ratio of 18.02, a P/E/G ratio of 3.03 and a beta of 1.27. Icon Plc has a 1-year low of $125.10 and a 1-year high of $211.00. The firm has a fifty day simple moving average of $179.90 and a 200 day simple moving average of $176.28. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.